ICTI Announces New President

May 22, 2006

Interactive Clinical Technologies Inc. (ICTI), an Almac Company announced today that Jim Murphy will succeed Richard McCann as President of ICTI in July 2006. Richard McCann will be moving to Northern Ireland to run Galen Limited, another Almac Company. Jim joined ICTI in 1999 as a Project Manager and has since held a number of key leadership positions including; Regional Director of Clinical Services, Vice President of Operations, and most recently, Vice President of Business Development and Marketing.

Sir Allen McClay, Chairman of Almac noted,

“Jim has a wealth of experience in the industry and within ICTI. He is well known to our customers and is an industry thought leader in the field of adaptive trial design. The broad perspective that he has established while leading various departments within the company will stand him in good stead for his new role. I am confident that Jim and the ICTI management team will continue to expand the business and build on the technology and service leadership of ICTI and Almac.”

About ICTI and Almac Group

ICTI offers technology-based services to the biopharmaceutical industry to increase the quality and efficiency of the clinical trial process. ICTI began offering clinical technologies in 1995 with the introduction of interactive voice response services (iVRS), and followed in 1999 with the launch of EDC software, iTrial EDC. Clients include more than two-thirds of the worlds leading pharmaceutical and biotechnology companies as well as numerous contract research organizations, governmental agencies, and academic medical centers. ICTI’s solutions have been used in more than 80 countries and 750 trials, and its experience spans all phases of clinical trial development (phases I-IV) and all therapeutic areas.

Almac through its affiliated companies (CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and Almac Diagnostic Services) provide a broad range of services across drug discovery, diagnostics, pharmaceutical research and development, manufacture of API, clinical trials and drug product manufacture. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland with additional operations in London and Edinburgh.

Contact Meghan Adams US: 267-685-4284 / [email protected]


Back to news